Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, has announced definitive agreements for a registered direct offering and concurrent private placement, aiming to raise approximately $2.9 million in gross proceeds. The company will issue 3,625,000 common shares at $0.795 per share and warrants to purchase an equal number of shares at an exercise price of $0.84 per share. The warrants are priced at $0.005 each. The transaction is expected to close on or about Aug. 14, 2026, subject to customary closing conditions, with Aegis Capital Corp. acting as the exclusive placement agent.
The net proceeds from this offering, combined with existing cash, cash equivalents, restricted cash, and investment-grade securities, will be allocated for working capital and general corporate purposes. This capital infusion is pivotal for Dyadic as it advances its proprietary Dapibus™ and C1 expression systems, which are designed to enable rapid, cost-effective, and flexible manufacturing of high-value proteins. These platforms are central to the company's mission to address the growing global demand for non-animal protein production across life sciences, food and nutrition, and bio-industrial markets.
The significance of this funding lies in its potential to accelerate Dyadic's commercialization efforts. By strengthening its balance sheet, the company can invest in R&D, scale up production capabilities, and pursue strategic partnerships. This is particularly important as industries increasingly seek sustainable and efficient alternatives to animal-derived proteins. Dyadic's technology offers a solution that is not only scalable but also environmentally friendly, aligning with global sustainability goals.
Investors and market observers view this move as a positive signal of confidence in Dyadic's business model and growth prospects. The offering provides the company with the financial runway to execute its strategic plan, which includes expanding its product pipeline and enhancing its market presence. As the demand for alternative proteins continues to rise, Dyadic is well-positioned to capitalize on this trend, making this funding a critical step in its journey to becoming a leader in the biotech sector.
For more details on the offering, visit https://ibn.fm/od7FJ. To learn more about Dyadic International and its innovative platforms, visit https://dyadic.com/.
